American Journal of Obstetrics & Gynecology
Volume 201, Issue 3 , Pages 230-240, September 2009

The management of preterm premature rupture of the membranes near the limit of fetal viability

Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, Ohio

Received 20 March 2009; received in revised form 1 May 2009; accepted 23 June 2009.

Article Outline

Preterm premature rupture of the membranes near the limit of fetal viability is an uncommon complication of pregnancy, affecting approximately 4 in 1000 gravidas. However, maternal, fetal, and neonatal complications resulting from this condition are significant and include chorioamnionitis, pulmonary hypoplasia, restriction deformities, fetal loss, and complications of extreme prematurity among surviving infants. In this article, we review the literature regarding pregnancy outcomes after preterm premature rupture of the membranes near the limit of viability, and the data on traditional and nontraditional interventions to improve outcomes. An approach to patients who present with preterm premature rupture of the membranes near the limit of viability will be proposed.

Key words: periviable, preterm premature rupture of membranes, previable

 

Few clinical situations in obstetrics are as challenging as preterm premature rupture of the membranes (PROM) near the limit of fetal viability. Although the term “midtrimester PROM” carried a similar connotation to periviable PROM in the 1970s and 1980s,1, 2, 3, 4, 5 currently the majority of infants born at 24-26 weeks' gestation will survive with aggressive medical care. Since Taylor and Garite1 reported on perinatal outcomes after PROM <26 weeks in 1984, practice patterns regarding antenatal corticosteroid administration and antibiotics have significantly changed. Although the incidence of PROM <24 weeks' gestational age is low (0.37%), the complications of this condition for both the mother and fetus are significant.6, 7, 8, 9, 10, 11, 12, 13 In the preparation of this article, we chose to focus on publications since 1994 with PROM between 14-24 weeks' gestational age (defined herein as “periviable PROM”). In this article, we review the origin and clinical course of periviable PROM. In addition, we summarize the available data regarding maternal and fetal outcomes and treatments to improve outcomes resulting from this morbid condition. In general, when evaluating any of the outcomes of these trials, it should be noted that all of these studies were retrospective and included only those patients amenable to expectant treatment on admission. In addition, many of these publications excluded patients with advanced labor, fibroids, previa, bleeding, or acute infection, and those who ultimately terminated the pregnancy based on prognosis alone.6, 7, 8, 9, 10, 11, 12, 13 This potentially exaggerates the overall latency, and underestimates the maternal and infant morbidities subsequent to periviable PROM as a whole.

For Editors' Commentary, see Table of Contents

Back to Article Outline

Etiology 

The etiology of periviable PROM is multifactorial. It is hypothesized that a weakness in the chorioamniotic membrane occurs as a result of either membrane stretch or degradation of the extracellular matrix.14 Multiple retrospective investigations have identified risk factors for early preterm PROM (Table 1). Specific risk factors include a history of cervical insufficiency, antepartum bleeding, multiple gestations, previous PROM or preterm labor, tobacco use, cervical cerclage, and amniocentesis. Although each of these factors is associated with periviable PROM, their predictive value is low. The rate of periviable PROM after a genetic amniocentesis has historically been reported as 1-2%.15, 16 However, recent data from large trials evaluating complications after genetic amniocentesis suggested the risk to be much lower, with the overall risk of pregnancy loss <24 weeks to be 1 in 1600.17 An investigation by Kilpatrick et al18 specifically compared risk factors between pregnancies complicated by PROM at 14-24 weeks and matched term deliveries. Significant risk factors for periviable PROM included a history of preterm delivery (odds ratio [OR], 15.2; 95% confidence interval [CI], 16.1–37.8), cervical incompetence in the incident pregnancy (OR, 12.7; 95% CI, 3.5–46.4), cerclage (OR, 10.3; 95% CI, 2.8–38.8), history of PROM (OR, 7.3; 95% CI, 2.5–22.3), history of cervical incompetence in a previous pregnancy (OR, 3.8; 95% CI, 1.2–11.8), and tobacco use (OR, 2.0; 95% CI, 1.1–3.9). Neither a history of chlamydia (OR, 0.7; 95% CI, 0.4–1.3) or gonorrhea (OR, 1.2; 95% CI, 0.5–2.8), nor a current infection with chlamydia (OR, 1.0; 95% CI, 0.5–2.1), gonorrhea (OR, 0.6; 95% CI, 0.1–5.3), or bacterial vaginosis (OR, 1.6; 95% CI, 0.7–3.6) were associated with periviable PROM.

TABLE 1. Factors associated with premature rupture of membranes near the limit of viability
ReferenceAntepartum bleeding, %History of preterm labor, %Cerclage, %History of PROM, %Multiple gestation, %Tobacco, %
Falk et al13––12.35.326.3–
Dinsmoor et al10–19.68.7–26.18.7
Kilpatrick et al189.851.911.811.8–18.6
Muris et al9––2.06.1––

PROM, premature rupture of membranes.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

Back to Article Outline

Clinical course 

The clinical characteristics of women with PROM near the limit of viability are presented in Table 2. The majority of women in these studies received antibiotic treatment (generally ampicillin ± erythromycin), with >50% receiving antenatal corticosteroids once the limit of viability was achieved. Among the included studies, the gestational age at membrane rupture ranged from 14–24 weeks (mean, 19.8–22.7 weeks) with a mean gestational age at delivery of 23.2–27.1 weeks. Pregnancy outcomes after conservative management of PROM near the limit of viability are presented in Table 3. Median latency to delivery varied between 6-13.0 days (range, 0–161 days), with mean latency of 14.1-39.4 days. Limited data are available about the impact of gestational age at rupture on the length of latency with PROM near the limit of viability. Based on data from 1 investigation, latency does not appear to vary by gestational age at rupture with median latencies of 8 days (1-161) with PROM <20 weeks, 4.5 days (2-106) with PROM between 20-21 weeks, and 12.0 days (1-112) with PROM between 23-23 weeks.13 These data appear to be similar to the historical investigations of midtrimester PROM that reported mean latency ranging from 12-21.5 days,1, 3, 4, 5, 19, 20, 21 but reflect the skewed nature of latency in this circumstance, which results from the rare occurrence of very prolonged latency after early preterm PROM. Older investigations noted that at least 50% of patients will deliver within 1 week of periviable PROM1, 3, 5, 19 with close to 75% delivered within 2 weeks. One recent investigation reported that 38% of women delivered within 1 week and 69% delivered within 5 weeks of periviable PROM.9 These data are likely more clinically useful for patient counseling.

TABLE 2. Characteristics of pregnancies with PROM near viability
ReferencenGA at PROM (wk)Mean GA at PROM (SD)Mean maternal age (y)Antibiotics (%)Steroids (%)Tocolytic (%)
Xiao et al11,a2814–2421.6(2.5)–Yes(89.3)Yes(75.0)–
Grisaru-Granovsky8,b2516–2422.7(1.0)–Yes(88.0)Yes(60.0)Yes(12.0)
Falk et al135714–2420.3(n/a)31.8(n/a)Yes(12.3)Yes(33.3)Yes(7.0)
Dinsmoor et al10,c4316–2422.0(median)30.3(7.0)Yes(86.0)Yes(n/a)No
Muris et al9,d4918–2421.1(n/a)29.3(n/a)Yes(69.4)Yes(28.6)Yes(14.3)
Everest et al6,e98<2419.8(2.5)–Yes(n/a)Yes(97.5)–

GA, gestational age; n/a, not applicable; PROM, premature rupture of membranes.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

aData reported for 28 liveborn infants admitted to neonatal intensive care department;

bAmpicillin and erythromycin were given from admission to delivery, antenatal steroids were given at 24 wk and repeated at 28 wk, indomethacin was given for tocolysis if indicated;

cThree declined expectant management, betamethasone was given routinely at 24 wk, antibiotics were given on admission;

dIncludes 20 terminations, ampicillin given on admission, betamethasone given routinely at 22 wk and repeated weekly;

eData reported only for 40 liveborn with latency ≥14 d, erythromycin given on admission, antenatal steroids given at 24 wk.

TABLE 3. Latency after conservatively managed PROM
ReferenceGA at PROM (wk)Mean GA at PROM (wk)Mean GA at delivery (wk)Mean latency (d)
Xiao et al11,a14–2421.6(2.5)27.1(2.1)39.4(23.9)
Grisaru-Granovsky816–2422.7(1.0)–15.6(n/a)
Falk et al1314–2420.3(n/a)–6.0b
Dinsmoor et al1016–2422.0b25.8(3.4)13.0b
Muris et al9,c18–2421.1(n/a)23.2(n/a)14.1(n/a)

GA, gestational age; n/a, not applicable; PROM, premature rupture of membranes.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

aData reported for 28 liveborn infants admitted to neonatal intensive care department;

bMedian;

cOutcomes for only 29 who did not terminate (n = 20) on presentation.

Table 4 presents maternal outcomes after periviable PROM. Because maternal outcomes with PROM <24 weeks are likely similar to those of midtrimester PROM, we present data from studies back through 1984, and provide summary estimates for these studies and for the subset of more recent publications with PROM ≤24 weeks. We found no statistically significant differences between the earlier and later cohorts except for a lower frequency of chorioamnionitis (31.8% vs 41.2%; P < .01) and a higher frequency of abruption (9.3% vs 4.3%; P < .01) after 1994. Overall, the most common maternal morbidity reported after periviable PROM is chorioamnionitis, with approximately 37% of women developing this complication. In addition, 11% will also develop endometritis. Of note, maternal sepsis and maternal death appear to be rare, with sepsis complicating 1 of every 100 pregnancies with periviable PROM, and only 1 investigation reporting a single maternal death (1/619 pregnancies) caused by sepsis.19

TABLE 4. Maternal outcomes after conservatively managed PROM
ReferenceGA at PROM (wk)nAmnionitis, n (%)Endometritis, n (%)Retained placenta, n (%)Abruption, n (%)Sepsis, n (%)Death, n (%)C/S, N (%)
Taylor and Garite116–255322(41.5)9(17.0)10(18.9)1(1.9)1(1.9)0(0.0)11(20.8)
Moretti and Sibai1916–2611846(39.3)13(11.0)–8(6.8)2(1.7)1(0.8)25(21.2)
Bengston et al315–265927(45.8)4(6.8)0(0.0)0(0.0)1(1.7)0(0.0)21(36.6)
Major and Kitzmitler519–257030(42.9)12(17.1)7(10.0)5(7.1)2(2.9)0(0.0)18(25.7)
Dowd and Permezel417–257128(39.4)1(1.4)18(25.3)2(2.8)0(0.0)0(0.0)9(12.7)
Hibbard et al2017–264434(77.2)2(4.5)–0(0.0)0(0.0)0(0.0)11(22.9)
Morales and Talley2115–259724(24.7)––––––
Hadi et al720–2517847(26.4)––5(2.8)––5(2.8)
Xiao et al11,a14–242813(46.4)–––––13(46.4)
Grisaru–Granovsky8,a16–2425–8(32.0)––0(0.0)0(0.0)7(28.0)
Falk et al13,a14–245718(31.6)10(17.5)6(10.5)–0(0.0)0(0.0)11(19.3)
Dinsmoor et al10,a16–244315(34.9)––12(27.9)––14(32.6)
Yang et al1216–267327(37.0)5(6.8)9(12.3)10(13.7)1(1.4)0(0.0)23(31.5)
Muris et al9,a18–244916(32.7)1(2.0)–5(10.2)1(2.0)0(0.0)–
Total 965347/940(36.9)65/619(10.5)50/383(13.1)48/714(6.7)8/619(1.3)1/619(0.2)168/819(20.5)
Total for studies published >1993 and with PROM ≤24 wka 20262/177(35.0)19/131(14.5)6/57(10.5)17/92(18.5)1/131(0.8)0/131(0.0)45/153(29.4)

C/S, cesarean section; GA, gestational age; PROM, premature rupture of membranes.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

aStudy after 1993 with PROM ≤24 wk.

Back to Article Outline

Perinatal morbidity and mortality 

Fetal death after PROM at or near the limit of viability is common at 31.6% (Table 5). Although survival has been reported with membrane rupture as early as 11 weeks' gestational age,22 a significant difference in survival can be found with PROM <22 weeks compared with PROM occurring >22 weeks (Table 6). It is important to reiterate that currently available data likely overstate the survival through exclusion of those not amenable to continued conservative treatment and those electing pregnancy terminations for persistent fluid leakage, oligohydramnios, or abnormal ultrasound findings.

TABLE 5. Perinatal mortality after conservatively managed PROM
ReferencenStillbirth, n (%)Liveborn, n (%)Neonatal death, n (%)Survival, n (%)
Xiao et al1128–a–12(42.9)16(57.1)
Grisaru-Granovsky825––17(68.0)8(32.0)
Falk et al13,b5730(52.6)27(47.4)12(21.1)15(26.3)
Dinsmoor et al105713(22.8)44(77.2)17(29.8)27(47.4)
Muris et al929–––12(41.4)
Everest et al67918(22.8)61(77.2)15(19.0)44(55.7)
Total27561/193(31.6)132/193(68.4)73/246(29.7)122/275(44.4)

PROM, premature rupture of membranes.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

aExcluded from analysis;

bOutcomes of multiple gestation pregnancies were reported as a single outcome, with the most favorable outcome reported.

TABLE 6. Survival after conservatively managed PROM
ReferenceGA at PROM (wk)PROM <22 wk (%)PROM ≥22 wk (%)
Xiao et al11,a14–242/11(18.1)14/17(82.4)
Grisaru-Granovsky816–242/10(20.0)5/15(33.3)
Falk et al13,b14–244/37(10.8)11/20(55.0)
Total 8/57(14.4)30/52(57.7)

GA, gestational age; PROM, premature rupture of membranes.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

aBoth survivors after PROM <22 wk were diagnosed with severe bronchopulmonary dysplasia;

bTwo cases of neonatal survival at <22 wk were in multiple gestation pregnancies after delivery of presenting fetus.

A summary of neonatal morbidities after conservative management of periviable PROM are presented in Table 7. Respiratory complications are frequent with 66% developing respiratory distress syndrome. Additional morbidities such as bronchopulmonary dysplasia and sepsis are also frequently present. Long-term outcomes including intact survival (survival without minor or major impairments) have been reported; however, most investigations have limited long-term follow-up and it is not possible to differentiate whether the reported outcomes are optimistic (underreporting of deaths) or pessimistic (disproportionate follow-up of those with morbidity).

TABLE 7. Neonatal morbidity and mortality after conservative management of premature rupture of membranes near the limit of viability
ReferencenPulmonary hypoplasia, n (%)RDS, n (%)BPD, n (%)Sepsis, n (%)IVH grade III-IV, n (%)ROP stage III, n (%)NEC, n (%)Contractures, n (%)Hospital duration (d, mean)Intact survival
Xiao et al11287(25.0)12(42.9)8(17.9)5(17.9)1(3.6)––––10/13a(76.9)
Grisaru-Granovsky8253(12.0)5(20.0)–5(20.0)2(8.0)2(8.0)1(4.0)0(0.0)––
Falk et al13273(11.1)––3(11.1)–––2(7.4)––
Dinsmoor et al1035b–29(82.9)8(22.9)12(34.3)4(11.4)–––71(median)17/27c(63.0)
Muris et al912d–10(83.3)–5(41.7)0(0.0)––0(0.0)27.4–
Everest et al640e10(25.0)36(90.0)14(35.0)1(2.5)0(0.0)1(2.5)––––
Total16723/120(19.2)92/140(65.7)30/103(29.1)31/167(18.6)7/140(5.0)3/65(4.6)1/25(4.0)2/64(3.1) 27/40(67.5)

BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

aFollow-up was completed by experienced pediatrician at adjusted age between 8 and 22 mo;

bOutcomes reported for 35 liveborn resuscitated and admitted to neonatal intensive care department;

cTen infants with serious sequelae at time of hospital discharge;

dOutcomes reported for 12 survivors;

eOutcomes reported for 40 liveborn with latency of at least 14 d.

To estimate the potential risks and benefits of latency for periviable PROM, Everest et al6 evaluated outcomes among neonatal survivors with prolonged (≥2 weeks in duration) periviable PROM in 2008. Of 98 women with PROM occurring <24 weeks, 40 (41%) delivered a liveborn infant after a latency of at least 14 days. Ten additional women delivered a stillbirth after prolonged latency with PROM <24 weeks. Among the 40 liveborn infants, the reported mortality was 30% (n = 12). Overall, 10 newborns were diagnosed with pulmonary hypoplasia, but only 1 of the neonatal deaths had an autopsy performed.

Few data are available regarding the prognosis of PROM after midtrimester genetic amniocentesis. Many of the retrospective trials either do not comment on this, or these patients are excluded from the analysis. Morales and Talley21 reported that 8 of 138 total women with PROM <25 weeks had an amniocentesis preceding rupture of membranes. Of these 8 women, 7 eventually resealed their membranes and had a term delivery. Gold et al16 reported on 603 cases of genetic amniocentesis, with 7 (1.2%) having subsequent rupture of membranes. In all 7 cases there was cessation of leakage of fluid with reaccumulation of a normal amount of amniotic fluid. A term delivery occurred in 6 of the 7, with 1 pregnancy ending with an intrauterine fetal death at 25 weeks.

Back to Article Outline

Pulmonary hypoplasia 

Pulmonary hypoplasia results from a number of conditions that are associated with fetal lung compression and oligohydramnios. Pulmonary hypoplasia is a serious complication of periviable PROM and mortality from this condition ranges between 50-100%.6, 12, 23, 24 On pathological assessment, there is a failure of proliferation of alveoli with a corresponding decrease in lung volume. Normal development of the lung occurs in 5 stages: embryonic, pseudoglandular, canalicular, saccular, and alveolar. Periviable PROM occurs in the late pseudoglandular phase (weeks 8-16) and the early canalicular phase (weeks 16-28) of development. In the pseudoglandular phase, the segmental bronchi divide and develop into the intrasegmental bronchial tree. In the canalicular phase there is development of terminal bronchioles with flattening of epithelium and development of type II pneumocytes. Lethal pulmonary hypoplasia rarely develops subsequent to oligohydramnios >26 weeks' gestation.25, 26

Many of the investigations included in this review did not routinely perform autopsies to determine the cause of neonatal death, and clinical definitions of pulmonary hypoplasia have been inconsistent. Hence, the exact incidence of this disease is likely underreported. Current data suggest that approximately 9-20% of newborns delivered after periviable PROM will develop pulmonary hypoplasia. Factors contributing to the development of pulmonary hypoplasia include gestational age at PROM, duration of latency, and residual amniotic fluid volume.24, 27 Blott and Greenough28 described a cohort of 30 pregnancies complicated with PROM between 15-28 weeks with latency of at least 14 days. Eight (27%) infants had pulmonary hypoplasia and 14 (46%) had limb deformities. Newborns were grouped according to the presence or absence of pulmonary hypoplasia and compressive limb abnormalities. Compared with infants without these complications, those with pulmonary hypoplasia had an earlier mean gestational age of PROM (17 vs 24 weeks) and longer mean latency (10 vs 5 weeks). A similar trend was found for limb deformities with earlier mean gestational age of PROM (18 vs 24 weeks) and longer mean latency (13 vs 5 weeks) noted for the infants with limb deformities. The relationship between pulmonary hypoplasia and latency is confounded by the fact that time is required for pulmonary hypoplasia to develop, and those delivered soon after PROM cannot have this condition.

Back to Article Outline

Ultrasound to predict fetal outcomes 

Several authors have evaluated the role of amniotic fluid volume on perinatal outcomes. Hadi et al7 evaluated the presence or absence of oligohydramnios (no visible 2-cm pocket of fluid). A total of 178 singleton pregnancies complicated by PROM between 20-25 weeks were included. In all, 107 (60.1%) were deemed to have at least 1 visible fluid pocket and 71 (39.9%) did not. The frequency of chorioamnionitis was higher (33.8 vs 21.5%; P = .07) and perinatal survival was lower (9.9% vs 85.0%; P < .01) in the group with severe oligohydramnios. For those who delivered between 26-34 weeks (n = 104), the frequency of chorioamnionitis was higher for those with severe oligohydramnios (69.2% vs 24.1%; P < .001), as was the incidence of perinatal death (69.2% vs 2.1%; P < .001). These results are similar to those reported by Xiao et al,11 who reported improved fetal survival among patients with an amniotic fluid index ≥5 cm after periviable PROM at 14-24 weeks' gestation (80.0% vs 30.8%; P < .01). In addition, both Muris et al9 and Grisaru-Granovsky et al8 reported a higher mean amniotic fluid index among survivors after PROM near the limit of viability (P < .05 for both).

The patient with persistent oligohydramnios appears to be at particular risk for pulmonary hypoplasia. Rotschild et al23 found less frequent pulmonary hypoplasia among newborns delivered with normal amniotic fluid volumes after PROM (6.7%) compared with those with oligohydramnios (20.9%). Overall, persistent oligohydramnios has a sensitivity of 52-100%, specificity of 41-82%, positive predictive value of 22-64%, and a negative predictive value of 89-100% for pulmonary hypoplasia.23, 24, 27, 29

Considerable effort has been directed toward assessment of fetal lung growth by ultrasound to predict pulmonary hypoplasia. In 1985, Callen et al30 demonstrated a progressive lag of thoracic growth in a fetus that developed pulmonary hypoplasia. Subsequently, various fetal measurements have been assessed such as thoracic circumference, lung length, and thoracic area. Some authors have attempted to correct for overall fetal size by including another fetal parameter such as femur length, heart area, or abdominal circumference. Table 8 presents results from studies that evaluated the predictive value of ultrasound for lethal pulmonary hypoplasia.29, 31, 32, 33, 34, 35 All of these studies were performed in patients at risk for pulmonary hypoplasia, including patients with PROM. Although sonographic measurements appear to be useful in the prediction of pulmonary hypoplasia, no one test is clearly preferable. Preliminary study of the role of estimated lung volumes by 3-dimensional ultrasound has been encouraging but not definitive.35

TABLE 8. Ultrasound prediction of pulmonary hypoplasia
AuthorPopulation studiednParameterAbnormalSensitivity (%)Specificity (%)PPV (%)NPV (%)Prevalence (%)Pathologic criteria
Vintzileos et al31Oligo/PROM31
TC

TA

TA-HA

TC/AC

TA/HA

(TA-HA)/TA

<5 percentile
33

33

50

33

66

83


57

71

71

85

85

85


40

50

60

66

80

83


50

55

62

60

75

85

69LW/BW + RAC
Ohlsson et al32Oligo/PROM58
TC

TC-FL

<5 percentile
80

80

55

60


90

97

97

100


80

92

86

100


90

91

87

90

28LW/BW <0.012 or RAC <1 SD of mean for GA
D'Alton et al33PROM16TC/AC<0.83 at 15 wk or <0.80 at term751001008037LW/BW <0.012
Yoshimura et al34PROM/renal anomalies/thanatophoric dwarfism51
TC

TA

TA-HA

LA

TC/AC

TA/HA

(TA-HA)/TA

LA/TA

<2 SD of mean
100

100

100

81

91

69

69

31


83

87

87

100

90

100

97

100


81

84

80

100

87

100

92

100


100

100

100

91

93

86

86

73

41LW/BW and RAC
Laudy et al29PROM31
TC

CC/TC

TC/AC

TAV (PP)

PSV (PP)

PDV (PP)

EDV (PP)

PI (PP)

TAV (MP)

PSV (MP)

PDV (MP)

EDV (MP)

PI (MP)

PROM ≤20 wk

PROM ≤24 wk

Oligo ≥8 wk

Oligo ≥6 wk

Oligo ≤1 cm

Oligo ≤2 cm


<5 percentile

>95 percentile

<5 percentile

<5 percentile

<5 percentile

<5 percentile

<5 percentile

>95 percentile

<5 percentile

<5 percentile

<5 percentile

<5 percentile

>95 percentile


94

76

69

69

63

44

50

56

71

43

43

57

29

78

100

89

100

78

100


38

50

71

76

90

90

86

76

80

80

70

90

75

77

45

59

50

82

32


52

52

61

69

83

78

73

64

71

60

50

80

44

58

43

47

45

64

38


90

75

77

76

76

68

69

70

80

67

64

75

60

89

100

93

100

90

100

29LW/BW and RAC
Gerards et al35PROM18
TC

TC/AC

TA/HA

3D LV

<5 percentile
50

50

100

83


75

75

58

100


50

50

54

100


75

75

100

92

33LB/BW or radiologic findings

AC, abdominal circumference; BW, Bodyweight; CC, cardiac circumference; EDV, end-diastolic velocity; FL, femur length; GA, gestational age; HA, heart area; LA, lung area; LV, lung volume; LW, lung weight; MP, middle pulmonary artery branch; NPV, negative predictive value; Oligo, oligohydramnios; PDV, peak diastolic velocity; PI, pulsatility index; PP, proximal pulmonary artery branch;PPV, positive predictive value; PROM, premature rupture of membranes; PSV, peak systolic velocity; RAC, radial alveolar count; TA, thoracic area; TAV, time-averaged velocity; TC, thoracic circumference; 3D, 3-dimensional.

Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

Back to Article Outline

Contractures/skeletal deformities 

The pattern of fetal restriction deformities occurring subsequent to periviable PROM are similar to those seen with Potter syndrome, and include abnormal facies (low-set ears, hypertelorism, receding chin, flattened nose, wrinkled skin), abnormal limb positions,36 and flattened hands and feet. The incidence of skeletal deformities after periviable PROM ranges from 1.5-38%. Rotschild et al23 reported on 88 newborns with prolonged PROM (≥7 days) at <29 weeks. The overall incidence of deformities was 20.4%, with increasing latency and severe oligohydramnios identified as significant risk factors. Fortunately, many of these are easily treated with physiotherapy and do not require surgery.37

Back to Article Outline

Management 

Antibiotics/corticosteroids/tocolytics 

For women who present with PROM at ≥24 weeks' gestational age, broad-spectrum antibiotics and antenatal corticosteroids have been shown to increase latency and improve neonatal outcomes.38 However, even with broad-spectrum antibiotics, 55% of patients with PROM >24 weeks will deliver within 48 hours, and 86% will deliver within 21 days. For many patients with periviable PROM, this may not be enough time to achieve fetal viability. To date, no randomized trials have specifically addressed the role of broad-spectrum antibiotic therapy in periviable PROM. Although the risks and benefits of antibiotic therapy for women who desire conservative management of periviable PROM are unproven, their use has increased over time from 0% in 1984 to 97% in 2008. Compared with patients not treated with antibiotics on admission, Morales and Talley21 reported a lower frequency of chorioamnionitis with antenatal ampicillin (12.9 vs 30.3%; P = .06). Both Xiao et al11 and Grisaru-Granovsky et al8 reported on neonatal survival with antenatal antibiotic treatment after periviable PROM. In the study by Grisaru-Granovsky et al,8 22 (88%) of 25 women with periviable PROM received ampicillin and erythromycin on admission and were continued on antibiotics until delivery. The exact antibiotic regimen was not specified by Xiao et al,11 however, 25 (89.3%) of 28 patients received some form of antibiotics before delivery. Overall, 47 (88%) of 53 patients were given therapy with improved survival noted for those who received antibiotics (51.1% vs 0%; P = .02). Although these results are encouraging, the current evidence is insufficient to guide either the use or timing of antibiotics in the setting of PROM near the limit of viability. It is unlikely that antibiotic therapy initiated long after membrane rupture will significantly enhance pregnancy outcomes.

A similar trend is observed in the use of antenatal corticosteroids. Although no specific recommendations exist for the use of antenatal corticosteroids in the setting of periviable PROM, many investigations report the administration of antenatal corticosteroids after viability has been reached. This can skew the association of steroids with survival because the achievement of viability alone would be associated with improved outcomes. Although a paucity of data is available on this topic, at least 4 publications have reported on infant survival according to steroid exposure3, 8, 11, 21 and are presented in Table 9. From these results, antenatal corticosteroid exposure appears to be associated with significant improvements. The role of rescue steroids remote from an initial course of antenatal steroids has not been determined.

TABLE 9. Antenatal corticosteroids and survival
ReferenceGA at PROM (wk)nReceived steroids, n (%)Survival with steroids, n (%)Survival without steroids, n (%)P
Xiao et al11,a14–242821(75.0)15(71.4)1(14.3).01
Grisaru-Granovsky8,b16–242515(60.0)7(46.7)1(10.0).05
Morales and Talley21,c15–256621(31.8)18(85.7)11(31.4)<.01
Bengston et al3,d15–265628(50.0)23(82.1)7(25.0)<.01

GA, gestational age; PROM, premature rupture of membranes.

aFrom 1-3 courses of corticosteroids were administered at weekly or every-other-week intervals;

bBetamethasone (2 doses of 12 mg intramuscularly at 24-h intervals) was administrated at 24 wk and repeated once if delivery was considered imminent between 28-34 wk of gestation;

cDexamethasone (2 doses 12 mg intramuscularly at 24-h intervals) was administered at 25 wk and then weekly;

dDosing regimen not specified.

The use of tocolytics with PROM is controversial,39 and its value in periviable PROM is not known. At best, tocolysis can offer the benefit of a few days of pregnancy prolongation and is unlikely to have any clinical impact when given before the limit of fetal viability. It has been postulated that tocolytic therapy might confer a brief prolongation of pregnancy and thereby allow more time for antibiotic therapy, however, this particular benefit is speculative.

Back to Article Outline

Nontraditional therapies: cervical sealants and amniofusion 

Several investigators have evaluated the use of cervical plugs or membrane sealants in the management of periviable PROM.40, 41, 42, 43, 44, 45 Although the exact therapy used in each of these investigations are different (gelatin sponge, platelets, cryoprecipitate, fibrin) the goal of each was to repair a defect in the amniotic membrane and allow for reaccumulation of amniotic fluid. In general, these investigations are limited in size and used other therapies including cerclage, tocolytics, and/or antibiotics. In addition, 2 of these investigations enrolled patients with iatrogenic PROM.42, 43 None offered a control group for comparison of outcomes. The reported survival for those treated ranged from 30-54%. The largest trial of cervical sealants, performed by Sciscione et al,45 evaluated an intracervical fibrin sealant in 12 women with spontaneous PROM <24 weeks' gestation. The mean gestational age at delivery was 27 weeks, and the mean latency was 48 days. Survival was 54%. Adverse events were not reported. Although the findings of these studies may be encouraging, the risks associated with these interventions remain unknown. Absent comparative data that suggest benefit without significant maternal risks, these treatments should not be incorporated into routine medical practice.

Transabdominal amniofusion for periviable PROM was evaluated in a trial by Vergani et al.46 A total of 18 women with PROM ≤25 weeks with oligohydramnios were treated with serial amniofusion and were compared with a historical cohort of 16 untreated patients. The authors reported no adverse events in the amniofusion-treated group, and found a lower incidence of pulmonary hypoplasia compared with control subjects (46% vs 86%; P = .03). Although the findings of this investigation are interesting, the frequency of pulmonary hypoplasia in the control group was unusually high and the biologic plausibility of amniofusion without correction of the membrane rupture is questionable. At present, the benefits of amniofusion for periviable PROM are unproven and the risks remain undetermined. Additional research is required before this therapy can be considered for routine clinical use.

Back to Article Outline

Recommendations 

Based on the available literature, we offer an algorithm for the management of PROM near the limit of viability (Figure). The patient with periviable PROM and no indication for immediate delivery should be extensively counseled regarding the risks and benefits of conservative management. This should include a realistic estimate of the potential neonatal outcomes and maternal risks. For patients who determine the risks of conservative management outweigh the potential benefits, delivery can be achieved with induction or by dilatation and evacuation. The optimal approach for delivery should be individualized based on patient characteristics, patient preference, available facilities, and physician experience.

  • View full-size image.
  • FIGURE. 

    Management algorithm for preterm premature rupture of membranes near the limit of fetal viability

  • Waters. The management of PROM of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009.

For the patient who desires conservative management, no data delineate an optimal approach. Initial care may include broad-spectrum antibiotics with strict bed rest and pelvic rest in conjunction with close surveillance for infection or abruption as an inpatient or outpatient. Women who are discharged should return immediately for fever, abdominal pain, a suspicious vaginal discharge, or bleeding. Hospitalization should be considered once viability is achieved to allow for early intervention for infection, abruption, labor, and abnormal fetal surveillance. Antenatal corticosteroids should be administered at this time.

After an initial ultrasound assessment, repeated evaluation can be performed every 2 weeks to asses amniotic fluid status (and the possibility of secondary membrane sealing) and fetal lung growth. If pulmonary hypoplasia becomes suspected before viability the patient may choose to reconsider the decision of expectant management.

Back to Article Outline

Summary 

Preterm PROM before fetal viability is a rare complication of pregnancy, but carries significant maternal morbidity, neonatal morbidity, and neonatal mortality. For the gravida who develops this obstetric complication, extensive counseling should be performed regarding the risks and benefits of conservative management. For a patient who desires conservative management of PROM before the limit of viability, serial assessments should be performed for signs of infection or labor. In addition, interval ultrasound examinations should be performed to asses for pulmonary hypoplasia. If these conditions arise, then conservative management may no longer be desirable for the patient. Limited data are available to guide the use of antenatal therapies such as antibiotics and corticosteroids to improve outcomes. However, the use of antenatal antibiotics to improve latency followed by antenatal corticosteroids once viability has been achieved is a reasonable approach. Future research should address what, if any, benefit cervical sealants confer for periviable PROM, and the role of tocolytic therapy and antibiotic therapy to improve latency and neonatal outcomes.

Back to Article Outline

References 

  1. Taylor J, Garite TJ. Premature rupture of membranes before fetal viability. Obstet Gynecol. 1984;64:615–620
  2. Beydoen SN, Yasin SY. Premature rupture of the membranes before 28 weeks: conservative management. Am J Obstet Gynecol. 1986;155:471–479
  3. Bengston JM, VanMarter LJ, Barss VA, et al. Pregnancy outcome after premature rupture of the membranes at or before 26 weeks' gestation. Obstet Gynecol. 1989;73:921–926
  4. Dowd J, Permezel M. Pregnancy outcome following preterm premature rupture of the membranes at less than 26 weeks' gestation. Aust N Z J Obstet Gynecol. 1992;32:120–124
  5. Major CA, Kitzmitler JL. Perinatal survival with expectant management of midtrimester rupture of membranes. Am J Obstet Gynecol. 1990;163:838–844
  6. Everest NJ, Jacobs SE, Davis PG, Begg L, Rogerson S. Outcomes following prolonged preterm premature rupture of the membranes. Arch Dis Child Fetal Neonatal Ed. 2008;93:F207–F211
  7. Hadi HA, Hodson CA, Stickland D. Premature rupture of the membranes between 20 and 25 weeks' gestation: role of amniotic fluid volume in perinatal outcome. Am J Obstet Gynecol. 1994;170:1139–1144
  8. Grisaru-Granovsky S, Eitan R, Kaplan M, et al. Expectant management of midtrimester premature rupture of membranes: a plea for limits. J Perinatol. 2003;23:235–239
  9. Muris C, Girard B, Creveuil C, et al. Management of premature rupture of membranes before 25 weeks. Eur J Obstet Gynecol Reprod Biol. 2007;131:163–168
  10. Dinsmoor MJ, Bachman R, Haney EI, et al. Outcomes after expectant management of extremely preterm premature rupture of the membranes. Am J Obstet Gynecol. 2004;190:183–187
  11. Xiao ZH, André P, Lacaze-Masmonteil T, et al. Outcome of premature infants delivered after prolonged premature rupture of membranes before 25 weeks of gestation. Eur J Obstet Gynecol Reprod Biol. 2000;90:67–71
  12. Yang LC, Taylor DR, Kaufman HH, et al. Maternal and fetal outcomes of spontaneous preterm premature rupture of membranes. J Am Osteopath Assoc. 2004;104:537–542
  13. Falk S, Campbell L, Lee-Parriz A, et al. Expectant management in spontaneous preterm premature rupture of membranes between 14 and 24 weeks' gestation. J Perinatol. 2004;24:611–616
  14. French JI, McGregor JA. The pathobiology of premature rupture of membranes. Semin Perinatol. 1996;20:344–368
  15. Tabor A, Madsen M, Obel EB, et al. Randomized controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1:1287–1296
  16. Gold RB, Goyert GL, Schwartz DB, et al. Conservative management of second-trimester post-amniocentesis fluid leakage. Obstet Gynecol. 1989;74:745–747
  17. Eddleman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol. 2006;108:1067–1072
  18. Kilpatrick SJ, Patil R, Connell J, et al. Risk factors for previable premature rupture of the membranes or advanced cervical dilatation: a case control study. Am J Obstet Gynecol. 2006;194:1168–1175
  19. Moretti M, Sibai BM. Maternal and perinatal outcome of expectant management of premature rupture of membranes in the midtrimester. Am J Obstet Gynecol. 1988;159:390–396
  20. Hibbard JU, Hibbard MC, Ismail M, et al. Pregnancy outcome after expectant management of premature rupture of the membranes in the second trimester. J Reprod Med. 1993;38:945–951
  21. Morales WJ, Talley T. Premature rupture of membranes at <25 weeks: a management dilemma. Am J Obstet Gynecol. 1993;168:503–507
  22. Hoekstra JH, de Boer R. Very early prolonged premature rupture of the membranes and survival. Eur J Pediatr. 1990;149:585–586
  23. Rotschild A, Ling EW, Puterman ML, et al. Neonatal outcome after prolonged preterm rupture of the membranes. Am J Obstet Gynecol. 1990;162:46–52
  24. Winn HN, Chen M, Amon E, et al. Neonatal pulmonary hypoplasia and perinatal mortality in patients with midtrimester rupture of amniotic membranes–a critical analysis. Am J Obstet Gynecol. 2000;182:1638–1644
  25. Moessinger AC, Collins MH, Baau WA, et al. Oligohydramnios induced lung hypoplasia: The influence of timing and duration in gestation. Pediatr Res. 1986;20:951–954
  26. Nimrod C, Varela-Gittings F, Machin G, et al. The effect of very prolonged membrane rupture on fetal development. Am J Obstet Gynecol. 1984;148:540–543
  27. Vergani P, Ghidini A, Locatelli A, et al. Risk factors for pulmonary hypoplasia in second trimester PROM. Am J Obstet Gynecol. 1994;170:1359–1364
  28. Blott M, Greenough A. Neonatal outcome after prolong rupture of the membranes starting in the second trimester. Arch Dis Child. 1988;63:1146–1150
  29. Laudy JA, Tibboel D, Robben SG, et al. Prenatal prediction of pulmonary hypoplasia: clinical, biometric, and Doppler velocity correlates. Pediatrics. 2002;109:250–258
  30. Callen NA, Colmorgan GH, Weiner S. Lung hypoplasia and prolonged preterm rupture membranes: a case report with implications for possible prenatal ultrasonic diagnosis. Am J Obstet Gynecol. 1985;151:756–757
  31. Vintzileos AM, Campbell WA, Rodis JF, et al. Comparison of six different ultrasonographic methods for predicting lethal fetal pulmonary hypoplasia. Am J Obstet Gynecol. 1989;161:606–612
  32. Ohlsson A, Fong K, Rose T, et al. Prenatal ultrasonic prediction of autopsy-proven pulmonary hypoplasia. Am J Perinatol. 1992;9:334–337
  33. D'Alton M, Mercer B, Riddick E, et al. Serial thoracic versus abdominal circumference ratios for the prediction of pulmonary hypoplasia in premature rupture of the membranes remote from term. Am J Obstet Gynecol. 1992;166:658–663
  34. Yoshimura S, Masuzaki H, Gotoh H, et al. Ultrasonographic prediction of lethal pulmonary hypoplasia: comparison of eight different ultrasonographic parameters. Am J Obstet Gynecol. 1996;175:477–483
  35. Gerards FA, Twisk JW, Fetter WP, et al. Two- or three-dimensional ultrasonography to predict pulmonary hypoplasia in pregnancies complicated by preterm premature rupture of the membranes. Prenat Diagn. 2007;27:216–221
  36. Perlman M, Williams J, Hirsch M. Neonatal pulmonary hypoplasia after prolonged leakage of amniotic fluid. Arch Dis Child. 1976;51:349–353
  37. Wenstrom KD. Pulmonary hypoplasia and deformations related to premature rupture of membranes. Obstet Gynecol Clin North Am. 1992;19:397–408
  38. Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial; National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. JAMA. 1997;278:989–995
  39. Mercer BM. Premature rupture of membranes: ACOG practice bulletin no. 80 (American College of Obstetricians and Gynecologists). Obstet Gynecol. 2007;109:1007–1019
  40. Uchide K, Terada S, Hamasaki H, et al. Intracervical fibrin instillation as an adjuvant to treatment for second trimester rupture of membranes. Arch Gynecol Obstet. 1994;255:95–98
  41. Reddy UM, Shah SS, Nemiroff RL, et al. In vitro sealing of punctured fetal membranes: potential treatment for midtrimester premature rupture of membranes. Am J Obstet Gynecol. 2001;185:1090–1093
  42. Quintero RA, Morales WJ, Allen M, et al. Treatment of iatrogenic previable premature rupture of membranes with intra-amniotic injection of platelets and cryoprecipitate (amniopatch): preliminary experience. Am J Obstet Gynecol. 1999;181:744–749
  43. O'Brien JM, Barton JR, Milligan DA. An aggressive interventional protocol for early midtrimester premature rupture of the membranes using gelatin sponge for cervical plugging. Am J Obstet Gynecol. 2002;187:1143–1146
  44. Quintero RA, Morales WJ, Kalter CS, et al. Transabdominal intra-amniotic endoscopic assessment of previable premature rupture of membranes. Am J Obstet Gynecol. 1998;179:71–76
  45. Sciscione AC, Manley JS, Pollock M, et al. Intracervical fibrin sealants: a potential treatment for early preterm premature rupture of the membranes. Am J Obstet Gynecol. 2001;184:368–373
  46. Vergani P, Locatelli A, Strobelt N, et al. Amnioinfusion for prevention of pulmonary hypoplasia in second-trimester rupture of membranes. Am J Perinatol. 1997;14:325–329

 Reprints not available from the authors.

PII: S0002-9378(09)00693-0

doi:10.1016/j.ajog.2009.06.049

American Journal of Obstetrics & Gynecology
Volume 201, Issue 3 , Pages 230-240, September 2009

Article Tools

* Image Usage & Resolution